Literature DB >> 25365110

Remote collection of questionnaires.

A Sargious1, S J Lee.   

Abstract

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease associated with rapid loss of function and radiographic damage. Treatment is targeted to achieve low disease activity/remission, as measured by various pooled indices comprised of laboratory measures, patient-derived, and physician-derived measures. Outside clinical trials, it can be difficult to obtain all these components at the time of the visit to provide immediate guidance. Subsequently, several pooled indices of patient reported outcomes (PROs) have been developed and shown to be equally and sometimes more effective as traditional assessor- and laboratory-derived measures in detecting treatment group and predicting long-term outcomes. With growing use of electronic medical record (EMR) and technology, many of these PROs can now be obtained remotely and directly incorporated into EMR to facilitate target to treat approach. Remotely collecting PROs through the internet allows better data capture, easier incorporation into EMR, and more frequent monitoring of patient's disease activity in between clinic visits for quicker assessment of adverse events and therapeutic efficacy. Adapting remotely collected PROs into clinical trials, clinical care, and long-term database has the potential for restructuring medical care while reducing costs and improving quality of care to achieve disease remission.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25365110

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  Using e-technologies in clinical trials.

Authors:  Carmen Rosa; Aimee N C Campbell; Gloria M Miele; Meg Brunner; Erin L Winstanley
Journal:  Contemp Clin Trials       Date:  2015-07-12       Impact factor: 2.226

2.  Predictors of pain and disability outcomes in one thousand, one hundred and eight patients who underwent lumbar discectomy surgery.

Authors:  Chad E Cook; Paul M Arnold; Peter G Passias; Anthony K Frempong-Boadu; Kristen Radcliff; Robert Isaacs
Journal:  Int Orthop       Date:  2015-04-01       Impact factor: 3.075

3.  Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis.

Authors:  Lisanne Renskers; Ron J J C van Uden; Anita M P Huis; Sanne A A Rongen; Steven Teerenstra; Piet L C M van Riel
Journal:  Clin Rheumatol       Date:  2018-09-12       Impact factor: 2.980

Review 4.  Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools.

Authors:  Piet van Riel; Rieke Alten; Bernard Combe; Diana Abdulganieva; Paola Bousquet; Molly Courtenay; Cinzia Curiale; Antonio Gómez-Centeno; Glenn Haugeberg; Burkhard Leeb; Kari Puolakka; Angelo Ravelli; Bernhard Rintelen; Piercarlo Sarzi-Puttini
Journal:  RMD Open       Date:  2016-11-24

Review 5.  Electronic case report forms and electronic data capture within clinical trials and pharmacoepidemiology.

Authors:  David A Rorie; Robert W V Flynn; Kerr Grieve; Alexander Doney; Isla Mackenzie; Thomas M MacDonald; Amy Rogers
Journal:  Br J Clin Pharmacol       Date:  2017-04-22       Impact factor: 4.335

6.  Development, usability and acceptability of an integrated eHealth system for spondyloarthritis in the Netherlands (SpA-Net).

Authors:  Casper Webers; Esther Beckers; Annelies Boonen; Yvonne van Eijk-Hustings; Harald Vonkeman; Mart van de Laar; Astrid van Tubergen
Journal:  RMD Open       Date:  2019-04-11

7.  Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey.

Authors:  Esther Chamorro-de-Vega; Rosa Romero-Jiménez; Vicente Escudero-Vilaplana; Arantza Ais-Larisgoitia; María Elena Lobato Matilla; Carlos M González; Luis Menchén; Ofelia Baniandrés; Lucía Ibares-Frias; Carmen Lobo-Rodríguez; Ana Herranz-Alonso; María Sanjurjo
Journal:  J Med Internet Res       Date:  2022-09-13       Impact factor: 7.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.